Pharming Group N.V. (PHAR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PHAR Revenue Growth
Revenue Breakdown
PHAR's revenue distribution by segment and geography
By Geography
PHAR Revenue Analysis (2014–2025)
As of May 8, 2026, Pharming Group N.V. (PHAR) generated trailing twelve-month (TTM) revenue of $376.0 million, reflecting strong growth of +14.8% year-over-year. The most recent quarter (Q4 2025) recorded $106.4 million in revenue, up 9.4% sequentially.
Looking at the longer-term picture, PHAR's 5-year compound annual growth rate (CAGR) stands at +12.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $377.2 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including LGND (+64.8% YoY), RARE (+13.3% YoY), and ACAD (+9.9% YoY), PHAR has underperformed the peer group in terms of revenue growth. Compare PHAR vs LGND →
PHAR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PHARCurrent | $376M | +14.8% | +12.2% | 5.1% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 KRYS | $389M | +25.1% | - | 41.5% |
PHAR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $377.2M | +26.9% | $331.6M | 87.9% | $19.4M | 5.1% |
| 2024 | $297.2M | +21.1% | $261.8M | 88.1% | $-8,621,000 | -2.9% |
| 2023 | $245.3M | +19.3% | $220.1M | 89.7% | $-5,387,000 | -2.2% |
| 2022 | $205.6M | +3.4% | $188.1M | 91.5% | $18.2M | 8.9% |
| 2021 | $198.9M | -6.3% | $177.7M | 89.4% | $13.6M | 6.8% |
| 2020 | $212.2M | +12.0% | $188.6M | 88.9% | $76.3M | 35.9% |
| 2019 | $189.4M | +22.5% | $165.5M | 87.4% | $68.2M | 36.0% |
| 2018 | $154.6M | +43.8% | $129.2M | 83.6% | $43.5M | 28.1% |
| 2017 | $107.5M | +544.1% | $92.6M | 86.1% | $26.3M | 24.4% |
| 2016 | $16.7M | +41.0% | $11.8M | 70.5% | $-12,136,637 | -72.7% |
See PHAR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHAR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHAR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
Is PHAR's revenue growth accelerating or slowing?
PHAR maintains +14.8% revenue growth, in line with its 5-year CAGR of +12.2%. TTM revenue stands at $376M. Growth rate remains consistent with historical average.
What is PHAR's long-term revenue growth rate?
Pharming Group N.V.'s 5-year revenue CAGR of +12.2% reflects the sustained expansion pattern. Current YoY growth of +14.8% is near this long-term average.
How is PHAR's revenue distributed by segment?
PHAR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.